

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

ANNOUNCEMENT
DELAY IN DESPATCH OF CIRCULAR IN RELATION TO
CONTINUING CONNECTED TRANSACTIONS

This announcement is made pursuant to Rule 14A.47 of the Listing Rules.

Reference is made to the announcement (the “**Announcement**”) of Kingworld Medicines Group Limited (the “**Company**”) dated 1 April 2021 in relation to the proposed annual caps for the three years ending 31 December 2023 of the transactions under each of the 2021 Master Distribution Agreements. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, the Company will despatch a circular (the “**Circular**”) containing, among other things, (i) details of the transactions under each of the 2021 Master Distribution Agreements and the proposed annual caps thereof; (ii) a letter from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders containing its advice on the 2021 Master Distribution Agreements and the proposed annual caps thereof; (iii) recommendation of the Independent Board Committee to the Independent Shareholders; and (iv) the notice convening the EGM, on or before 27 April 2021.

As additional time is required to prepare and finalise the information to be included in the Circular, the date of despatch of the Circular is expected to be postponed to a date on or before 7 May 2021.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 26 April 2021

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.